Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma.

ABSTRACT: Immune Checkpoint Inhibitor (ICI) therapy has revolutionized treatment for advanced melanoma; however, only a subset of patients benefit from this treatment. Despite considerable efforts, the Tumor Mutation Burden (TMB) is the only FDA-approved biomarker in melanoma. However, the mechanisms underlying TMB association with prolonged ICI survival are not entirely understood and may depend on numerous confounding factors. To identify more interpretable ICI response biomarkers based on tumor mutations, we train classifiers using mutations within distinct biological processes. We evaluate a variety of feature selection and classification methods and identify key mutated biological processes that provide improved predictive capability compared to the TMB. The top mutated processes we identify ar

SUBMITTER: Patterson A 

PROVIDER: S-EPMC9485158 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature